Primary central nervous system lymphoma (2024)

de Koning, M. E., Hof, J. J., Jansen, C., Doorduijn, J. K., Bromberg, J. E. C., & van der Meulen, M. (2023). Primary central nervous system lymphoma. Journal of Neurology, 271(5), 2906-2913. https://doi.org/10.1007/s00415-023-12143-w

de Koning, Myrthe E. ; Hof, Jurrit J. ; Jansen, Casper et al. / Primary central nervous system lymphoma. In: Journal of Neurology. 2023 ; Vol. 271, No. 5. pp. 2906-2913.

@article{786a0f9a2c684d62a48143dd73194e7f,

title = "Primary central nervous system lymphoma",

abstract = "Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma (NHL) manifesting in the brain, spinal cord, cerebrospinal fluid and/or eyes, in the absence of systemic manifestations. With an increasing incidence and a 30% 5-year overall survival if promptly treated, timely diagnosis and subsequent treatment is paramount. The typical MRI appearance for PCNSL is a solitary or multiple T2-hypointense, hom*ogeneous gadolinium-enhancing lesion with restricted diffusion. Dexamethasone treatment might compromise and delay the diagnosis. Hallmark of treatment is induction with intravenous high-dose methotrexate consisting polychemotherapy followed by consolidation treatment. Consolidation treatment consists of either whole brain radiotherapy (WBRT) or autologous stem cell transplantation (ASCT). Given the (cognitive) side effects of WBRT, ASCT is increasingly being used as the first choice of treatment.",

author = "{de Koning}, {Myrthe E.} and Hof, {Jurrit J.} and Casper Jansen and Doorduijn, {Jeanette K.} and Bromberg, {Jacoline E.C.} and {van der Meulen}, Matthijs",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023.",

year = "2023",

month = dec,

day = "19",

doi = "10.1007/s00415-023-12143-w",

language = "English",

volume = "271",

pages = "2906--2913",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "D. Steinkopff-Verlag",

number = "5",

}

de Koning, ME, Hof, JJ, Jansen, C, Doorduijn, JK, Bromberg, JEC & van der Meulen, M 2023, 'Primary central nervous system lymphoma', Journal of Neurology, vol. 271, no. 5, pp. 2906-2913. https://doi.org/10.1007/s00415-023-12143-w

Primary central nervous system lymphoma. / de Koning, Myrthe E.; Hof, Jurrit J.; Jansen, Casper et al.
In: Journal of Neurology, Vol. 271, No. 5, 19.12.2023, p. 2906-2913.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Primary central nervous system lymphoma

AU - de Koning, Myrthe E.

AU - Hof, Jurrit J.

AU - Jansen, Casper

AU - Doorduijn, Jeanette K.

AU - Bromberg, Jacoline E.C.

AU - van der Meulen, Matthijs

N1 - Publisher Copyright:© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023.

PY - 2023/12/19

Y1 - 2023/12/19

N2 - Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma (NHL) manifesting in the brain, spinal cord, cerebrospinal fluid and/or eyes, in the absence of systemic manifestations. With an increasing incidence and a 30% 5-year overall survival if promptly treated, timely diagnosis and subsequent treatment is paramount. The typical MRI appearance for PCNSL is a solitary or multiple T2-hypointense, hom*ogeneous gadolinium-enhancing lesion with restricted diffusion. Dexamethasone treatment might compromise and delay the diagnosis. Hallmark of treatment is induction with intravenous high-dose methotrexate consisting polychemotherapy followed by consolidation treatment. Consolidation treatment consists of either whole brain radiotherapy (WBRT) or autologous stem cell transplantation (ASCT). Given the (cognitive) side effects of WBRT, ASCT is increasingly being used as the first choice of treatment.

AB - Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma (NHL) manifesting in the brain, spinal cord, cerebrospinal fluid and/or eyes, in the absence of systemic manifestations. With an increasing incidence and a 30% 5-year overall survival if promptly treated, timely diagnosis and subsequent treatment is paramount. The typical MRI appearance for PCNSL is a solitary or multiple T2-hypointense, hom*ogeneous gadolinium-enhancing lesion with restricted diffusion. Dexamethasone treatment might compromise and delay the diagnosis. Hallmark of treatment is induction with intravenous high-dose methotrexate consisting polychemotherapy followed by consolidation treatment. Consolidation treatment consists of either whole brain radiotherapy (WBRT) or autologous stem cell transplantation (ASCT). Given the (cognitive) side effects of WBRT, ASCT is increasingly being used as the first choice of treatment.

UR - http://www.scopus.com/inward/record.url?scp=85180178048&partnerID=8YFLogxK

U2 - 10.1007/s00415-023-12143-w

DO - 10.1007/s00415-023-12143-w

M3 - Article

C2 - 38112784

AN - SCOPUS:85180178048

SN - 0340-5354

VL - 271

SP - 2906

EP - 2913

JO - Journal of Neurology

JF - Journal of Neurology

IS - 5

ER -

de Koning ME, Hof JJ, Jansen C, Doorduijn JK, Bromberg JEC, van der Meulen M. Primary central nervous system lymphoma. Journal of Neurology. 2023 Dec 19;271(5):2906-2913. doi: 10.1007/s00415-023-12143-w